Clinical trials
Haploidentical Hematopoietic Stem Cell Transplantation clinical trials
Below are recruiting haploidentical hematopoietic stem cell transplantation clinical trials, each written for real people, not researchers. We’re tracking 82 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07791849Recruiting
Comparing two stomach protectors after stem cell transplant
This study compares two medications, GMPA and PPI, that protect the stomach during a stem cell transplant. It aims to see which one is better at preventing stomach problems and reducing the risk of a complication called graft-versus-host disease (aGVHD), where donor cells attack the patient's body.
HangzhouAges 12–70 - NCT07791576RecruitingPhase 2
Custom dosing of anti-thymocyte globulin for stem cell transplant
This trial tests whether giving anti-thymocyte globulin (ATG) based on a person's own body chemistry can reduce side effects and improve outcomes in stem cell transplants. It is for people with certain blood cancers who are in their first or second remission.
Beijing, Beijing MunicipalityAges 14–65 - NCT06158828RecruitingPhase 1/Phase 2
Natural Killer Cells After Half-Matched Stem Cell Transplant for High-Risk AML
This study tests a new way to prevent leukemia from returning after a half-matched stem cell transplant. It uses specially activated natural killer cells to attack remaining cancer cells. This may help people with high-risk or relapsed AML who have few other options.
St Louis, MissouriAges 18 years+ - NCT07012044RecruitingPhase 1
Cedazuridine and decitabine after stem cell transplant for childhood leukemia
This trial tests if adding two chemotherapy drugs (cedazuridine and decitabine) along with a growth factor (filgrastim) can help prevent leukemia from coming back after a stem cell transplant. It is for children and young adults with high-risk acute myeloid leukemia who are in remission after transplant.
Birmingham, AlabamaAges Up to 21 years - NCT05011422RecruitingPhase 1
Stem cell transplant using half-matched donor for kids with blood cancer
This study tests a special stem cell transplant for children and young adults with certain high-risk blood cancers or bone marrow diseases. It uses a half-matched family donor and a technique to remove specific cells, which may lower the risk of side effects and help the body accept the new cells.
St Louis, MissouriAges Up to 30 years - NCT06657391RecruitingPhase 2
Study of a new drug to prevent graft-versus-host disease in thalassemia patients
This trial tests a drug called an anti-CD25 antibody to see if it can prevent graft-versus-host disease (a condition where donor cells attack the body) in people with transfusion-dependent thalassemia who are getting a stem cell transplant from a partially matched or unrelated donor.
Maoming, GuangdongAges 3–20 - NCT06639854Recruiting
CMV immunity test to guide antiviral prevention after transplant
This trial uses a blood test to measure your immune system's ability to fight CMV, a common virus after transplant. The results will help your doctors decide if you can safely stop taking the antiviral medication letermovir earlier to avoid unnecessary side effects.
Houston, TexasAges 18 years+ - NCT06076226Recruiting
Donor telomere length and leukemia transplant outcomes
This trial looks at whether the length of telomeres (the protective caps at the ends of chromosomes) in donor blood cells affects recovery for people with acute leukemia who receive a stem cell transplant. It aims to see if a simple donor blood test can predict how well the transplant works.
Hangzhou, ZhejiangAges 5–90 - NCT06041893Recruiting
Stem cell transplant with gentler immune therapy
This trial offers a stem cell transplant from a half-matched (haploidentical) donor for children. It uses an early medicine to calm the immune system and a lower dose of a drug to prevent rejection and graft-versus-host disease.
SeoulAges Any age - NCT04022239RecruitingPhase 1/Phase 2
Bendamustine to prevent transplant immune complications
This early-phase study tests whether giving the drug bendamustine (with or without another chemo drug) can lower the risk of graft-versus-host disease (GVHD) after a stem cell transplant. GVHD is an immune reaction where the donor’s cells attack your body. If it works and is safe, it could improve outcomes after transplant.
Houston, TexasAges 18–70 - NCT07693881Recruiting
Preventing EBV reactivation with rituximab after stem cell transplant in children
This trial tests whether adding a drug called rituximab to the standard transplant plan can help prevent Epstein-Barr virus (EBV) from reactivating in children receiving a half-matched stem cell transplant. It may help reduce a common viral complication after transplant.
GuangzhouAges Up to 18 years - NCT07214688RecruitingPhase 2
Transplant Prep with Chemo, Radiation, and GVHD Prevention for Blood Cancers
This trial tests a standard transplant preparation (chemotherapy and low-dose radiation) followed by a special drug (PTCy) to prevent graft-versus-host disease after a donor stem cell transplant for blood cancers. It may help improve transplant success and reduce complications.
Washington D.C., District of ColumbiaAges 18–65 - NCT07101588RecruitingPhase 4
Ruxolitinib and decitabine before stem cell transplant for AML
This trial tests whether adding two drugs (ruxolitinib and decitabine) to the standard chemotherapy before a stem cell transplant can help prevent leukemia from coming back. It is for people with acute myeloid leukemia who have a suitable donor and are otherwise healthy enough for transplant.
Beijing, Beijing MunicipalityAges 14–75 - NCT06075563Recruiting
Total Lymphoid Irradiation for Children's Stem Cell Transplant
This trial tests a special type of radiation (total lymphoid irradiation) as part of the preparation for a stem cell transplant from a half-matched donor. It aims to make the transplant safer and more effective for children who need a transplant but don't have a fully matched sibling donor.
Hong KongAges Up to 18 years - NCT05762211RecruitingPhase 2
Oral probiotic to prevent complications after stem-cell transplant
This Phase 2 study tests an oral “fecal microbiotherapy” treatment given before and around an allogeneic (donor) stem-cell transplant to help prevent transplant-related complications. It may help by improving gut and immune function during the high-risk transplant period.
AntwerpAges 50 years+ - NCT06034535RecruitingPhase 2
A stem cell transplant trial using special donor cells
This trial tests a new way to give donor cells after a stem cell transplant to help the body accept them. It may help patients who need a transplant but don't have a perfectly matched donor.
Hong KongAges Up to 18 years - NCT06912347Enrolling by invitation
Herbal therapy to prevent infection after stem cell transplant
This trial tests whether a special herbal treatment applied to the skin can help prevent infections around the bottom that are caused by diarrhea after a stem cell transplant. It may be an option for people who are getting a transplant for the first time.
Shanghai, Shanghai MunicipalityAges 14–70 - NCT07244419RecruitingEarly Phase 1
Preventing stem cell transplant rejection in children
This early-phase trial tests a medication to prevent rejection of donated stem cells in children. It's for patients who are at high risk for their transplant to fail.
Cincinnati, OhioAges Any age - NCT07648992RecruitingPhase 4
ATG dosing strategy for unrelated donor stem cell transplant
This trial tests a personalized approach to using ATG (a medicine that reduces immune rejection) in patients receiving stem cell transplants from unrelated donors for blood cancers. The goal is to improve transplant success while reducing side effects by tailoring ATG doses to individual patients.
Beijing, Beijing MunicipalityAges 14–65 - NCT06529731RecruitingPhase 2
Interferon-Gamma and Donor Cells for Relapsed Leukemia After Transplant
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
St Louis, MissouriAges 18 years+ - NCT07719946RecruitingPhase 2
Lower dose chemo after stem cell transplant for blood cancers
This trial tests whether a lower dose of the chemotherapy drug cyclophosphamide given after a stem cell transplant is safe and effective for people with blood cancers. The goal is to reduce side effects while still helping prevent the cancer from coming back.
Navi Mumbai, MaharashtraAges 18 years+ - NCT03279094RecruitingPhase 1
Testing a half-matched bone marrow transplant for sickle cell
This early-phase study tests whether a “half-matched” donor bone marrow transplant, with special medicines to calm the immune system before transplant, can improve outcomes for people with sickle cell disease. It may help high-risk patients who have frequent complications and don’t have a fully matched donor.
Duarte, CaliforniaAges 1–30 - NCT03665675RecruitingEarly Phase 1
Immune cell treatment to control CMV or adenovirus after transplant
This early-phase study tests donor immune cells made to recognize CMV (a virus) or adenovirus, given to help control virus reactivation after a solid organ or bone marrow transplant. It may help reduce ongoing or worsening viral infection when standard antiviral medicines are hard to tolerate or not working well.
Columbus, OhioAges 1–85 - NCT04195633RecruitingPhase 2
Haploidentical donor stem cell transplant to treat blood cancers
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
Seattle, WashingtonAges 6 months+
Hear when a new Haploidentical Hematopoietic Stem Cell Transplantation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for haploidentical hematopoietic stem cell transplantation?
- Yes. Clin2 currently lists 82 recruiting haploidentical hematopoietic stem cell transplantation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a haploidentical hematopoietic stem cell transplantation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a haploidentical hematopoietic stem cell transplantation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation
- Allogeneic Hematopoietic Stem Cell Transplantation Recipient
- Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Autologous Hematopoietic Stem Cell Transplantation
- Haploidentical Stem Cell Transplantation
- Hematopoietic Stem Cell Transplant
- Stem Cell Transplantation
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.